ArticleBMC public health2016
Determinants of multidrug-resistant tuberculosis in Henan province in China: a case control study.
Article in BMC public health, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 1 synthesis or guideline pooled it, 61 citations in OpenAlex.
- Causal association of antibiotic use and resistant tuberculosis infection: Casecontrol meta-analysisRevista espanola de salud publica · 2018Pooled it
- Factors associated with screening failure and study withdrawal in multidrug-resistant TB.The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease · 2022Trial
- Risk factors of multi-drug-resistant tuberculosis among tuberculosis patients in Bagmati Province, Nepal: a matched case-control study.BMC infectious diseases · 2026Article
- Prevalence and determinants of tuberculosis and COVID-19 among patients with presumptive tuberculosis in a Nigerian tertiary hospital.BMC infectious diseases · 2026Article
- Assessing the determinants of drug-resistant tuberculosis in selected hospitals in Tigray region, Northern Ethiopia: a case-control study.Journal of health, population, and nutrition · 2025Article
- Drug resistance patterns, trends, and risk factors for multidrug resistance of tuberculosis in Wenzhou, China: a ten-year retrospective analysis (2014-2023).Frontiers in medicine · 2025Article
- Determinants of drug-resistant tuberculosis in Hunan province, China: a case-control study.BMC infectious diseases · 2024Article
- Assessment of risk factors associated with multi-drug resistant tuberculosis (MDR-TB) in Gulu regional referral hospital.African health sciences · 2023Article
- The Microbiome as Part of the Contemporary View of Tuberculosis Disease.Pathogens (Basel, Switzerland) · 2022Review
- Predicting resistance to fluoroquinolones among patients with rifampicin-resistant tuberculosis using machine learning methods.PLOS digital health · 2022Article
- Drug Resistance Patterns and Trends in Patients with Suspected Drug-Resistant Tuberculosis in Dalian, China: A Retrospective Study.Infection and drug resistance · 2022Article
- Determinants of Multidrug-ResistantInfection and drug resistance · 2022Article
- Socio-economic drivers of drug-resistant tuberculosis in Africa: a scoping review.BMC public health · 2021Article
- Article
- Factors Associated with Multi-Drug Resistant Tuberculosis among TB Patients in Selected Treatment Centers of Amhara Region: A Case-Control Study.Ethiopian journal of health sciences · 2021Article
- Drug-resistant tuberculosis: an experience from Qatar.The Libyan journal of medicine · 2020Article
- Prevalence of Antibiotic-Resistant Pulmonary Tuberculosis in Bangladesh: A Systematic Review and Meta-Analysis.Antibiotics (Basel, Switzerland) · 2020Article
- Characteristics of pulmonary multidrug-resistant tuberculosis patients in Tigray Region, Ethiopia: A cross-sectional study.PloS one · 2020Article
- Factors associated with multidrug-resistant tuberculosis (MDR-TB) in Bhutan: A nationwide case-control study.PloS one · 2020Article
- Determinants of Drug-Resistant Tuberculosis in Southern Ethiopia: A Case-Control Study.Infection and drug resistance · 2020Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMulti-drug resistance (MDR) has been a cause of concern for tuberculosis (TB) control in both developed and developing countries. This study described the characteristics and risk factors associated with MDR-TB among 287 cases and 291 controls in Henan province, China.
methodsA hospital-based case-control study was conducted between June 2012 and December 2013. The study subjects were selected using multistage probability sampling. Multivariate conditional logistic regression models were used to determine the risk factors associated with MDR-TB.
resultsThe following risk factors for MDR-TB were identified: previous TB treatment (AOR = 4.51, 95% CI: 3.55-5.56), male sex (AOR = 1.09, 95% CI: 0.24-1.88), high school or lower education degree (AOR = 1.87, 95% CI: 1.27-2.69), unemployment (AOR = 1.30, 95% CI: 0.78-2.52), long distance of residence from the health facility (AOR = 6.66,95% CI: 5.92-7.72), smoking (AOR = 2.07, 95% CI: 1.66-3.19), poor knowledge regarding MDR-TB (AOR = 2.06, 95% CI: 1.66-2.92), traveling by foot to reach the health facility (AOR = 1.85, 95% CI: 1.12-3.09), estimated amount of time to reach the health facility was greater than 3 h (AOR = 1.42, 95% CI: 0.51-2.35), social stigma (AOR = 1.17, 95% CI: 0.27-2.03), having an opportunistic infection (AOR = 1.45, 95% CI: 0.58-2.4), more than 3 TB foci in the lungs (AOR = 1.98, 95% CI: 1.49-3.25), total time of first treatment was more than 8 months (AOR = 1.39, 95% CI: 0.65-2.54), adverse effects of anti-TB medication (AOR = 2.39, 95% CI: 1.40-3.26), and more than 3 prior episodes of anti-TB treatment (AOR = 1.83, 95% CI: 1.26-2.80).
conclusionThe identified risk factors should be given priority in TB control programs. Additionally, there is a compelling need for better management and control of MDR-TB, particularly through increasing laboratory capacity, regular screening, enhancing drug sensitivity testing, novel MDR-TB drug regimens, and adherence to medication.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.